CM
REPL icon

Crestline Management’s Replimune Group REPL Stock Holding History

Crestline Management’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-172,202
Closed -$2.09M – 508
2024
Q4 		$2.09M Buy
+172,202
New +$2.09M 0.07% 272

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crestline Management's REPL Position: Q1 2025 in Review

Crestline Management sold out of Replimune Group (REPL) in Q1 2025, closing a stake of 172,202 shares — an estimated $2.09M sold.

Crestline Management first reported a position in REPL in Q4 2024 and held it in 1 quarter. The position peaked at $2.09M in Q4 2024. 167 funds tracked by Wall St. Rank hold REPL as of Q1 2025.

  • Crestline Management reported no remaining Replimune Group position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 172,202 Replimune Group shares in Q1 2025, an estimated $2.09M.
  • Crestline Management first reported a position in Replimune Group in Q4 2024 and held it in 1 quarter.
  • Crestline Management's Replimune Group position peaked at $2.09M in Q4 2024.
  • 167 funds tracked by Wall St. Rank held Replimune Group as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.